Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23844664 | 0.82 | ALDH1A1 (0.34) | ALDH1A1MAPK1TDP1CA1CA12 | |
| SCHEMBL17570927 | 0.82 | ALDH1A1 (0.34) | ALDH1A1MAPK1TDP1CA1CA12 | |
| SCHEMBL6000229 | 0.82 | HMGCR (0.38) | ALDH1A1MAPK1TDP1CA1CA12 | |
| SCHEMBL22104689 | 0.81 | ALDH1A1 (0.33) | ALDH1A1MAPK1TDP1CA1CA12 | |
| SCHEMBL12700619 | 0.81 | HTT (0.36) | ALDH1A1MAPK1TDP1CA1CA12 | |
| SCHEMBL24805287 | 0.78 | EPHX2 (0.32) | ALDH1A1MAPK1EPHX2 | |
| SCHEMBL22876869 | 0.78 | GRM4 (0.31) | — | |
| SCHEMBL24208216 | 0.78 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL15934038 | 0.78 | CYP2D6 (0.34) | ALDH1A1MAPK1TDP1CA1CA2 | |
| SCHEMBL24657981 | 0.77 | PGA5 (0.33) | ALDH1A1MAPK1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | ALDH1A1 4781/4885MAPK1 4460/4885TDP1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.